You are here

Article Text

Article menu
Download PDFPDF
Letter
Which 5-ASA?
  1. J C Mansfield
  1. Royal Victoria Infirmary, Newcastle NE1 4LP, UK; john.mansfield@nuth.northy.nhs.uk

https://doi.org/10.1136/gut.52.5.771

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    I read Dr Travis’ therapy update (

    Gut2002;51:548–9
    OpenUrlFREE Full Text

    ) with interest; the topic is timely in a market about to be challenged by new generic mesalazine brands. I note the choice of time dependent mesalazine (Pentasa) but, if mesalazine is to be relied upon exclusively, some evidence suggests Pentasa may not be the best choice. The recent study by Kruis and colleagues1 in the maintenance of remission in ulcerative colitis (UC) found that with Pentasa 1.5 g/day, the six month remission rate was 56.8% compared with 77.5% with balsalazide 3 g twice daily (p=0.045).

    The assertion that the advantages of the azo bond delivery to the distal colon can be matched by simply increasing the dose of pH dependent (Asacol) or time dependent release (Pentasa) has not been …

    View Full Text